These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29731738)

  • 41. The role of insulin-like growth factor system in the adrenocortical tumors.
    Altieri B; Colao A; Faggiano A
    Minerva Endocrinol; 2019 Mar; 44(1):43-57. PubMed ID: 29963827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin Receptor Isoform A Modulates Metabolic Reprogramming of Breast Cancer Cells in Response to IGF2 and Insulin Stimulation.
    Vella V; Nicolosi ML; Giuliano M; Morrione A; Malaguarnera R; Belfiore A
    Cells; 2019 Sep; 8(9):. PubMed ID: 31480557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells.
    Schedlich LJ; Yenson VM; Baxter RC
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):56-64. PubMed ID: 23831640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rho guanosine 5'-triphosphatases differentially regulate insulin-like growth factor I (IGF-I) receptor-dependent and -independent actions of IGF-II on human trophoblast migration.
    Shields SK; Nicola C; Chakraborty C
    Endocrinology; 2007 Oct; 148(10):4906-17. PubMed ID: 17640993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
    Iams WT; Lovly CM
    Clin Cancer Res; 2015 Oct; 21(19):4270-7. PubMed ID: 26429980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo.
    Tarnowski M; Tkacz M; Zgutka K; Bujak J; Kopytko P; Pawlik A
    BMC Cancer; 2017 Aug; 17(1):532. PubMed ID: 28793874
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primate mammary gland insulin-like growth factor system: cellular localization and regulation by sex steroids.
    Zhou J; Anderson K; Bievre M; Ng S; Bondy CA
    J Investig Med; 2001 Jan; 49(1):47-55. PubMed ID: 11217147
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monitoring the activation state of the insulin-like growth factor-1 receptor and its interaction with protein tyrosine phosphatase 1B using bioluminescence resonance energy transfer.
    Blanquart C; Boute N; Lacasa D; Issad T
    Mol Pharmacol; 2005 Sep; 68(3):885-94. PubMed ID: 15976035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma.
    de Groot S; Röttgering B; Gelderblom H; Pijl H; Szuhai K; Kroep JR
    Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism.
    Ellis BC; Graham LD; Molloy PL
    Biochim Biophys Acta; 2014 Feb; 1843(2):372-86. PubMed ID: 24184209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IGF1R signalling and its inhibition.
    Riedemann J; Macaulay VM
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S33-43. PubMed ID: 17259557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Yak IGF2 Promotes Fibroblast Proliferation Via Suppression of IGF1R and PI3KCG Expression.
    Zhang Q; Wang Q; Gong J; Du J; Zhang Y; Zhao X
    Genes (Basel); 2018 Mar; 9(3):. PubMed ID: 29558395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.
    Zumsteg A; Caviezel C; Pisarsky L; Strittmatter K; García-Echeverría C; Hofmann F; Christofori G
    Mol Cancer Res; 2012 Jun; 10(6):800-9. PubMed ID: 22562956
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1.
    LeRoith D; Yakar S
    Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):302-10. PubMed ID: 17315038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibiting the m
    Dai TT; Li YZ; Hu HT; Zhao YM; Peng HY; Bai WD; Wang JW
    World J Oncol; 2024 Feb; 15(1):100-113. PubMed ID: 38274714
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stabilization of oncogenic transcripts by the IGF2BP3/ELAVL1 complex promotes tumorigenicity in colorectal cancer.
    Li K; Huang F; Li Y; Li D; Lin H; Ni R; Zhang Q; Zhao M; Huang S; Zou L; Huang C
    Am J Cancer Res; 2020; 10(8):2480-2494. PubMed ID: 32905413
    [TBL] [Abstract][Full Text] [Related]  

  • 57. All-atom structural models for complexes of insulin-like growth factors IGF1 and IGF2 with their cognate receptor.
    Vashisth H; Abrams CF
    J Mol Biol; 2010 Jul; 400(3):645-58. PubMed ID: 20488191
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulation of insulin-like growth factor binding protein-3 messenger ribonucleic acid expression by insulin-like growth factor I.
    Bale LK; Conover CA
    Endocrinology; 1992 Aug; 131(2):608-14. PubMed ID: 1379162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The RNA m
    Ge L; Rui Y; Wang C; Wu Y; Wang H; Wang J
    Cell Death Dis; 2024 Mar; 15(3):192. PubMed ID: 38448411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature.
    O'Neill A; Shah N; Zitomersky N; Ladanyi M; Shukla N; Uren A; Loeb D; Toretsky J
    Sarcoma; 2013; 2013():450478. PubMed ID: 23431249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.